uniQure BV (QURE) PT Raised to $68 at Leerink, 'topline results from the pivotal Phase 1/2 study of AMT-130 in Huntington's disease (HD) as a definitive win'
Tweet Send to a Friend
(Updated - September 24, 2025 1:08 PM EDT)
Leerink Partners analyst Joseph Schwartz raised the price target on uniQure ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst Joseph Schwartz raised the price target on uniQure ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
